Recent Trends in Clinical Trials Related to Carrier-Based Drugs

Tagami, Tatsuaki; Ozeki, Tetsuya

doi:10.1016/j.xphs.2017.02.026

Cited by 51 publications

(18 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…17 Usage of colloidal carriers for drug delivery has gained a lot of attention towards the effective treatment of brain disorders as they target the active site very efficiently, (in comparison to other routes of administration). 18,19 Delivering these nanocarriers through nasal route also enables effective brain targeting and minimizing systemic exposure, when compared to oral route. 20 In recent years, NLC, which is considered as a modified version of solid lipid nanoparticle (SLN), where drug gets encapsulated in solid-lipid and liquid-lipid is increasingly preferred over SLN, as it overcomes major disadvantages of SLN, such as low drug loading and drug expulsion related issues.…”

Section: Introductionmentioning

confidence: 99%

Direct Brain Targeted Nanostructured Lipid Carriers for Sustained Release of Schizophrenic Drug: Formulation, Characterization and Pharmacokinetic Studies

Sivadasu¹,

Gowda²,

Subramani³

et al. 2019

IJPER

View full text Add to dashboard Cite

Background: Systemic drug delivery in schizophrenia is a major challenge, owing to the Blood-brain Barrier (BBB) and P-glycoprotein related effects. Consequently, herein an attempt is made to systemically deliver the most desirable schizophrenia drug, Quetiapine Fumarate (QF) via non-invasive intranasal route using Nanostructured Lipid Carrier (NLC) approach. Materials and Methods: The desired QF loaded NLCs were developed using central composite statistical design and the developed formulations were monitored for improving QF bioavailability and their brain targeting efficacies. Results: The optimized formulation displayed a 2-fold increase (compared to virgin QF) in ex-vivo nasal diffusion at the 6 th hr, with no sign of structural damage (upon histopathological examinations). While, QF blood-brain ratio showed 10-fold increase for NLCs administered through nasal route (in comparison to intravenous route), thereby supporting prolonged retention of QF at the site of action. Similarly, the concentration of QF (in the brain) delivered via nasal route exhibited 4-fold increment at all-time points thereby supporting a potential nose to brain transport and effective bypassing of BBB. Conclusion: The results obtained infers that non-invasive intranasal route can be used as a potential alternative to conventional treatment options towards efficient management of schizophrenia.

show abstract

Section: Introductionmentioning

confidence: 99%

Direct Brain Targeted Nanostructured Lipid Carriers for Sustained Release of Schizophrenic Drug: Formulation, Characterization and Pharmacokinetic Studies

Sivadasu¹,

Gowda²,

Subramani³

et al. 2019

IJPER

View full text Add to dashboard Cite

show abstract

“…Various nanomedicines have entered clinical trials globally 1) and food and drug administrations have to date approved over 50 formulations such as liposomes, polymeric nanoparticles, drug nanoparticles, and metal-based nanoparticles.…”

mentioning

confidence: 99%

The Use of an Efficient Microfluidic Mixing System for Generating Stabilized Polymeric Nanoparticles for Controlled Drug Release

Morikawa

Tagami

Hoshikawa

et al. 2018

Biological & Pharmaceutical Bulletin

Self Cite

View full text Add to dashboard Cite

Microfluidics is a promising system for efficiently optimizing the experimental conditions for preparing nanomedicines, such as self-assembled nanoparticles. Poly(lactic-co-glycolic acid) (PLGA) nanoparticles are promising drug carriers allowing sustained drug release. Here, we encapsulated the model drug curcumin, which has many pharmacological activities, into PLGA nanoparticles and investigated the effects of experimental conditions on the resulting PLGA nanoparticles using a microfluidics system with a staggered herringbone structure that can stir solutions through chaotic advection. The total flow rate and flow rate ratio of the solutions in the microfluidics system affected the diameters, polydispersity index, and encapsulation efficiency of the resulting PLGA nanoparticles and produced small, homogenous PLGA nanoparticles. The incorporation of polyethylene glycol (PEG)-PLGA into the PLGA nanoparticles reduced the particle size and improved the encapsulation efficiency. Initial burst release from the PLGA nanoparticles was prevented by the incorporation of PEG2000-PLGA. Curcumin-loaded PEGylated PLGA nanoparticles showed cytotoxicity similar to that of other formulations. This microfluidics system allows high throughput and is scalable for the efficient preparation of PLGA nanoparticles and PEGylated PLGA nanoparticles. Our results will be useful for developing novel PLGA-based polymer nanoparticles by using the microfluidics.

show abstract

“…Such drug carriers are usually injected intravenously and can accumulate at the tumor site either by passive targeting using the enhanced permeation and retention (EPR) effect 5,6 or by targeting the carrier to specific receptors of tumor tissues 4 . This approach improves the drug efficiency while decreasing side effects and patients' pain [6][7][8] . The efficiency can be further improved by controlling the drug release, using carriers sensitive either to the characteristics of the tumor tissue (pH, temperature or redox potential) 9 or to an external stimulus (light, cold plasma, radiowave, magnetism, ultrasound...) 10 .…”

Section: Introductionmentioning

confidence: 99%

Ultrasound-triggered delivery of paclitaxel encapsulated in an emulsion at low acoustic pressures

et al. 2020

View full text Add to dashboard Cite

show abstract

Recent Trends in Clinical Trials Related to Carrier-Based Drugs

Cited by 51 publications

References 40 publications

Direct Brain Targeted Nanostructured Lipid Carriers for Sustained Release of Schizophrenic Drug: Formulation, Characterization and Pharmacokinetic Studies

Direct Brain Targeted Nanostructured Lipid Carriers for Sustained Release of Schizophrenic Drug: Formulation, Characterization and Pharmacokinetic Studies

The Use of an Efficient Microfluidic Mixing System for Generating Stabilized Polymeric Nanoparticles for Controlled Drug Release

Ultrasound-triggered delivery of paclitaxel encapsulated in an emulsion at low acoustic pressures

Contact Info

Product

Resources

About